1. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
- Author
-
Lieven Pouillon, P. van Dam, Peter B. Vermeulen, Cecile Colpaert, S. Van Laere, Mark M. Kockx, K. A. Schats, C. Van Berckelaer, François Bertucci, C. Rypens, Luc Dirix, M. Parizel, Wiebren A.A. Tjalma, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Department of Medical Oncology, St-Augustinus, Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,MESH: Mastectomy ,[SDV]Life Sciences [q-bio] ,CD8-Positive T-Lymphocytes ,B7-H1 Antigen ,0302 clinical medicine ,MESH: Aged, 80 and over ,Surgical oncology ,Antineoplastic Combined Chemotherapy Protocols ,MESH: B7-H1 Antigen ,MESH: Lymphocytes, Tumor-Infiltrating ,skin and connective tissue diseases ,Mastectomy ,Aged, 80 and over ,MESH: Aged ,MESH: Middle Aged ,Inflammatory breast cancer (IBC) ,Immune checkpoint modulators ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,MESH: CD8-Positive T-Lymphocytes ,Neoadjuvant Therapy ,3. Good health ,MESH: Antineoplastic Combined Chemotherapy Protocols ,Chemotherapy, Adjuvant ,MESH: Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,Cohort ,Stromal tumour-infiltrating lymphocytes (sTIL) ,MESH: Inflammatory Breast Neoplasms ,Female ,Inflammatory Breast Neoplasms ,Research Article ,Adult ,medicine.medical_specialty ,Stromal cell ,Programmed death-ligand 1 (PD-L1) ,MESH: Neoadjuvant Therapy ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Inflammatory breast cancer ,lcsh:RC254-282 ,Disease-Free Survival ,MESH: Prognosis ,03 medical and health sciences ,Immune system ,Breast cancer ,Lymphocytes, Tumor-Infiltrating ,Stroma ,Internal medicine ,medicine ,Adjuvant therapy ,Humans ,Immune response ,Aged ,MESH: Humans ,business.industry ,MESH: Adult ,medicine.disease ,Survival Analysis ,MESH: Disease-Free Survival ,Human medicine ,Stromal Cells ,MESH: Stromal Cells ,business ,MESH: Female - Abstract
Background Inflammatory breast cancer (IBC) is a rare and rapidly progressive form of invasive breast cancer. The aim of this study was to explore the clinical evolution, stromal tumour-infiltrating lymphocytes (sTIL) infiltration and programmed death-ligand 1 (PD-L1) expression in a large IBC cohort. Patients and methods Data were collected prospectively from patients with IBC as part of an international collaborative effort since 1996. In total, 143 patients with IBC starting treatment between June 1996 and December 2016 were included. Clinicopathological variables were collected, and sTIL were scored by two pathologists on standard H&E stained sections. PD-L1 expression was assessed using a validated PD-L1 (SP142) assay. A validation cohort of 64 patients with IBC was used to test our findings. Results Survival outcomes of IBC remained poor with a 5-year overall survival (OS) of 45.6%. OS was significantly better in patients with primary non-metastatic disease who received taxane-containing (neo)adjuvant therapy (P = 0.01), had a hormone receptor-positive tumour (P = 0.001) and had lower cN stage at diagnosis (P = 0.001). PD-L1 positivity on immune cells (42.9%) was higher in IBC than in non-IBC in both our patient samples and the validation cohort. Furthermore, PD-L1 expression predicted pCR (P = 0.002) and correlated with sTIL infiltration (P
- Published
- 2019